Leveraging AI and ML in Drug R&D: Current and Future Impacts to the Life Sciences Industry

Tune into Episode #2 of the LifeSci Search podcast with Andy Cronin (President & Co-Founder) and Ayesha Price (Sr. Director, Executive Search) as they host Iris Grossman (Chief Therapeutics Officer, Eleven Therapeutics) and Shahram Ebadollahi (Operating Partner, ARCHIMED & Former Chief Data Officer, Novartis) on the topic of AI and ML tools in Drug R&D. We get insights on how the tech is being leveraged in biotech and pharma along the R&D process, overall impact so far, thinking around AI and ML among leadership teams & boards, and perspectives on the competition for AI and ML talent within Life Sciences industry.

Tune into Episode #1 of the LifeSci Search Podcast.

In the clinical setting, the time it takes to address a serious problem can make the difference between life and death. To save as much time as possible, the necessary material – a vessel to do a coronary bypass, for example – needs to be readily available. However, due to the organic nature of that material, acquisition may take more time than you have, and the nature of the end-product may be suboptimal. Enter Humacyte. Using human-sourced cells, Humacyte creates Human Acellular Vessels (HAVs) that are non-immunogenic and available on demand. HAVs are in Phase 3 testing in the settings of both arteriovenous (AV) access, as needed for kidney dialysis, and trauma, as seen in severe injury, such as a war wounds. This indication has attracted the attention of the US Department of Defense and the Ukrainian army – where compassionate use is already underway. And, this is just the beginning. Listen in as Humacyte’s CEO Dr. Laura E. Niklason tells the Humacyte story.

Tune into this 17-minute chat with Erez Raphael, CEO of DarioHealth (NASDAQ: DRIO).

CDK and RAS-targeting drugs already exist, but in the setting of oncology, if it’s not curative, it’s not enough. As a former practicing oncologist, Onconova’s CEO Dr. Steven Fruchtman knows this and has spent his career at the bench, and now the boardroom, working to improve and provide such drugs for cancer patients. His CDK 4/6 drug, Narazaciclib, a drug with a much-improved toxicity profile relative to competitors, will commence a Phase 1/2a trial in endometrial cancer in Q1 2023. Onconova’s RAS inhibitor, Rigosertib, has shown activity in all flavors of KRAS mutations and is currently being tested in a Phase 2 investigation of checkpoint-resistant NSCLC patients. Tune in for a discussion of the next critical readouts.

Tune into this 9-minute chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc. (NYSE: PLX).

Tune into this 17-minute chat with Martin Welschof, CEO of BioInvent (STO: BINV).

Tune into this 11-minute chat with Raphi Levy, CFO of Alpha Tau Medical Ltd. (NASDAQ: DRTS).

In this 13-minute chat, Amir London, CEO of Kamada Ltd. (NASDAQ: KMDA), discusses the growing commercial business of the company, including six FDA-approved products for rare and serious conditions, and its innovative development pipeline, targeting areas of significant unmet medical need.

In this 15-minute chat, Rob Etherington, President & CEO of Clene, Inc. (NASDAQ: CLNN) discusses the potential for nanosuspensions to improve cellular energy production and treat neurodegenerative diseases, along with Clene’s future directions.